Adenotonsillotomy Noninferior to Adenotonsillectomy in Peds OSA

Share this content:
Adenotonsillotomy Noninferior to Adenotonsillectomy in Peds OSA
Adenotonsillotomy Noninferior to Adenotonsillectomy in Peds OSA

WEDNESDAY, March 22, 2017 (HealthDay News) -- Adenotonsillotomy (ATT) is noninferior to adenotonsillectomy (ATE) for children aged 2 to 6 years with obstructive sleep apnea (OSA), according to a study published online March 20 in Pediatrics.

Anna Borgström, M.D., from Karolinska University Hospital in Stockholm, and colleagues randomized 79 children aged 2 to 6 years with OSA to ATT or ATE (40 and 39, respectively). At baseline and one-year post-surgery, participants underwent polysomnography (PSG) and questionnaire OSA-18.

The researchers found that the mean between-group difference in the primary outcome of change in apnea-hypopnea index (AHI) was 0.83 (95 percent confidence interval, −3.2 to 4.9), which did not exceed the noninferiority margin of 5. AHI decreased after ATE from a median of 12.7 to 2.0; after ATT, AHI decreased from 15.8 to 4.0. Significant improvements of PSG and OSA-18 questionnaire outcomes were seen for both groups, with no significant between-group difference. Thirteen percent of children in the ATT group needed repeated surgery for tonsil regrowth and OSA recurrence.

"The results suggest that ATT is noninferior to ATE in treating pediatric OSA regarding PSG outcomes after one year. ATT could be considered an alternative to ATE for treatment of pediatric OSA," the authors write. "However, after ATT, there is a non-negligible risk of recurrence of OSA, and this should be taken into account when selecting surgical method."

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »